Why did Pfizer suspend sales of Premarin vaginal cream in India, and what is the impact on patients?

Pfizer suspended sales of Premarin vaginal cream in India due to 'certain supply challenges', as stated by Trupti Wagh, Pfizer's senior director of media relations for APAC; the suspension has significantly reduced estrogen therapy options for millions of Indian women experiencing menopause-related symptoms, particularly those suffering from genitourinary syndrome of menopause (GSM), as Premarin accounted for over half of all units sold in its category and 37% of India's conjugated estrogen market by value in the 12 months ended June 2026.

What are the current treatment alternatives for GSM in India following Premarin's suspension?

Following Premarin's suspension, the only other locally available option for GSM in India is Evalon, an estriol-based vaginal cream marketed by Torrent Pharmaceuticals, according to Dr. Sukhpreet Patel, a gynecologist and founder of MenopauseWize; she emphasized that India has 'essentially only Premarin and Evalon' — highlighting a severe scarcity of alternatives such as creams, ovules, or vaginal rings that are widely available globally.

Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges

Jul 16, 2026

Pfizer suspended Premarin vaginal cream sales in India due to supply challenges, impacting millions of women needing estrogen therapy. The product accounted for 37% of India's conjugated estrogen market, leaving patients with few alternatives amid scarce treatment options.

reuters

2026-07-16

Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges

Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges

FAQ